Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

Celyad Oncology (CYAD) News Today

Celyad Oncology logo
Celyad Oncology SA (CYADB.XC)
CSBR Champions Oncology, Inc.
Celyad Announces Management Change
Celyad Oncology Share Price (CYAD.BR)
Celyad Oncology to Terminate ADR Program
Celyad Oncology SA (CYAD.BR)
Celyad Oncology (CYADY) Earnings Dates & Reports
Celyad Oncology SA (CYADY)
Celyad Oncology announces receipt of Nasdaq notice
Celyad Oncology Appoints Georges Rawadi As CEO - Quick Facts
Celyad Oncology Appoints Georges Rawadi as Its New CEO
Celyad Oncology announces non-cash impairment
Celyad Oncology: Letter to Shareholders
Celyad Oncology SA - Letter to Shareholders
Celyad Oncology SA (CYAD)
Get Celyad Oncology News Delivered to You Automatically

Sign up to receive the latest news and ratings for CYAD and its competitors with MarketBeat's FREE daily newsletter.

This is treason (Ad)

If you missed it, my emergency election broadcast is now available - but will be removed soon

Click here to watch it now.

CYAD Media Mentions By Week

CYAD Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CYAD
News Sentiment

0.00

0.43

Average
Medical
News Sentiment

CYAD News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CYAD Articles
This Week

0

0

CYAD Articles
Average Week

Get Celyad Oncology News Delivered to You Automatically

Sign up to receive the latest news and ratings for CYAD and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:CYAD) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners